Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8618045
APP PUB NO 20120277142A1
SERIAL NO

13513803

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • HANALL BIOPHARMA CO., LTD.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jeong, Jae Kap Suwon-si, KR 19 18
Jun, Sung Soo Seongnam-si, KR 39 261
Kim, Eun Sun Suwon-si, KR 187 3293
Kim, Ha Na Suwon-si, KR 52 379
Kim, Song Young Suwon-si, KR 4 7
Kim, Sung Wuk Seongnam-si, KR 51 282
Park, Seung Kook Seoul, KR 24 20
Song, Yeon Jung Yongon-si, KR 15 15

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 30, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00